CLINICAL TRIAL: ACTION TO CONTROL CARDIOVASCULAR RISKS IN DIABETES (ACCORD) TRIA

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 雅阁试验旨在评估控制2型（成人发病）糖尿病的不同方法，同时减少高血压和高胆固醇引起的心血管问题的风险。 将在60个中心招募1万名受试者;老年医学研究中心将有大约150名受试者。 这三种干预措施都涉及FDA批准的药物治疗。所有受试者将接受糖尿病治疗; 50%将接受额外的血脂治疗，50%将接受血压治疗。 主要结局是首次发生重大心血管疾病事件，如卒中或非致死性MI。 其次，将评价CV事件、健康相关生活质量、成本效益、死亡率和微血管结局的治疗差异。 结果将通过实验室检查、自我报告问卷和体格检查来衡量。 监测将由老年研究中心（GRC）的工作人员进行。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The ACCORD trial is designed to evaluate different methods of controlling Type 2 (adult onset) diabetes while diminishing the risks of cardiovascular problems from high blood pressure and high cholesterol. Ten thousand participants in 60 centers will be enrolled; there will be approximately 150 enrollees at the Geriatric Research Center site. The three interventions all involve FDA-approved pharmacologic treatments. All subjects will receive treatment for diabetes; 50% will receive additional lipid treatment, and 50% will receive blood pressure treatment. The primary outcome is the first occurrence of a major cardiovascular disease event such as stroke or non-fatal MI. Secondarily, treatment differences in CV events, health-related quality of life, cost effectiveness, mortality, and microvascular outcomes will be evaluated. Outcomes will be measured by lab tests, self-reported questionnaires, and physical examinations. Monitoring will be done by the staff of the Geriatric Research Center (GRC).